PHARMACYTE BIOTECH INC (PMCB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.49-0.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PMCB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers
PMCB — officer change
Dated 2026-04-02
The filing describes an amendment to the Company’s equity incentive plan, which is not a management change.
Why it matters: A drop in sector revenue growth could signal a broader slowdown. This would impact Pharmacyte's performance.
Worry ifSector revenue growth has been below average. This has happened for two months in a row.
Less concerning ifSector revenue growth remains above its median for the same period.
Why it matters: The earnings report will show if the company can improve its financial performance. Investors will look for signs of recovery.
Watch forThe earnings report shows revenue growth. It is higher than the last quarter. There is a way to make money.
Also watch forEarnings report shows continued losses and no clear plan for improvement.
Why it matters: A drop in revenue growth could signal a slowdown in the healthcare sector. This could impact Pharmacyte's performance.
Worry ifRevenue growth in the healthcare sector falls below its median of 5%.
Less concerning ifRevenue growth in the healthcare sector stays above its median.
Why it matters: If revenue growth slows, it may signal a problem in Pharmacyte's business model. This could affect investor confidence.
Worry ifPharmacyte's revenue growth drops below the sector median of 5%.
Less concerning ifRevenue growth stays above the sector median of 5%.
Why it matters: Pharmacyte's performance is linked to the health care sector. If sector growth picks up, it may help Pharmacyte's recovery.
Supportive ifSector revenue growth speeds up again. It is now above 9%.
Worry ifSector revenue growth slows down. It is now below 9%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$271 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $786 loss on $10,000 · 7.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,060 loss on $10,000 · 60.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.